Cisplatin Treatment Options

A collection of 1441 research studies where Cisplatin is the interventional treatment. These studies are located in the United States . Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-Small Cell Lung Cancer.

Home

All Treatments

Cisplatin

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

NCT02690558

Active Not Recruiting

The purpose of this study is to evaluate whether adding pembrolizumab (Keytruda) to the combination of gemcitabine and cisplatin will improve shrinkage of the tumor before having a cystectomy, for people with muscle-invasive bladder cancer (MIBC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/06/2025

Locations: North Carolina Cancer Hospital (UNC), Chapel Hill, North Carolina +1 locations

Conditions: Bladder Cancer

Learn More ›

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

NCT03174275

Active Not Recruiting

Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN. These participants are eligible for surgery. Previous research with a similar therapy regimen resulted in high rates of cancer shrinkage, high rates of avoiding radiation and its side effects, high cure rate and good quality of life. Radiation can be very toxic. The purpose on this study is to try to avoid radiation. If the participants are not on this study they would be receiving radiation as it is standard treatment of their cancer. In the last study with a similar regimen, about a third of cancers had a pathologic complete response with the first part of the study. This means that the chemotherapy had killed the cancer. The investigators are trying to improve the regimen further with a goal of increasing this rate of complete response to the first part of therapy. The investigators also hope that by improving results in the first part, that more people will be cured and that long term quality of life (especially speech and swallowing) will be improved, both compared to standard therapies and to the last study. Doctors do not know how this therapy will effect the participants. There is no guarantee that this study will benefit the participants. The prior study used a combination of chemotherapy consisting of carboplatin, paclitaxel and a third targeted anti-cancer drug. In this study the investigators are testing the combination of carboplatin, nano-albumin bound paclitaxel and durvalumab. Nano-albumin bound paclitaxel has been shown to be more active against other types of squamous cancers than regular paclitaxel. It is FDA approved for squamous lung cancer, but experimental for head and neck cancer. Durvalumab is an experimental drug that uses the body's own immune system to fight the cancer. Doctors hope that combining Durvalumab with 2 chemotherapy drugs will be effective in treating SCCHN. Durvalumab on its own has been studied in patients with SCCHN and initial results have shown that some subjects' cancer has responded to it. The purpose of this study is to test a combination of chemotherapy to hopefully both increase the number of subjects that respond to therapy while also decreasing the number of side effects that subjects experience. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/05/2025

Locations: Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina +1 locations

Conditions: Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer

Learn More ›

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

NCT03143153

Completed

The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/05/2025

Locations: Local Institution - 0191, Mobile, Alabama +189 locations

Local Institution - 0191, Mobile, Alabama

Arizona Cancer Center, Tucson, Arizona

Usc/Norris Comprehensive Cancer Center, Los Angeles, California

Local Institution - 0188, Denver, Colorado

University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida

Local Institution - 0186, Miami, Florida

Local Institution - 0225, Tampa, Florida

Local Institution - 0074, Atlanta, Georgia

Local Institution - 0032, Marietta, Georgia

Hackensack Meridian Jersey Shore University Medical Center, Neptune, New Jersey

Oncology Associates Of Oregon, Pc, Eugene, Oregon

Northwest Cancer Specialists, P.C., Portland, Oregon

Local Institution - 0210, Dallas, Texas

Local Institution - 0028, Houston, Texas

Local Institution - 0190, Roanoke, Virginia

Local Institution - 0203, Morgantown, West Virginia

Local Institution - 0050, Capital Federal, Buenos Aires

Local Institution - 0086, Rosario, Santa FE

Local Institution - 0048, Buenos Aires, Not set

Local Institution - 0087, La Rioja, Not set

Local Institution - 0232, Tamworth, New South Wales

Local Institution - 0011, Douglas, Queensland

Local Institution - 0010, Murdoch, Western Australia

Local Institution - 0241, Salzburg, Not set

Local Institution - 0017, Salvador, Bahia

Local Institution - 0227, Ipatinga, Minas Gerais

Local Institution - 0021, Ijui, RIO Grande DO SUL

Local Institution - 0016, Porto Alegre, RIO Grande DO SUL

Local Institution - 0019, Barretos, Sao Paulo

Local Institution - 0226, Jau, Sao Paulo

Local Institution - 0018, São José do Rio Preto, São Paulo

Local Institution - 0228, Rio de Janeiro, Not set

Local Institution - 0020, Sao Paulo, Not set

Local Institution - 0095, Moncton, New Brunswick

Local Institution - 0082, Montreal, Quebec

Local Institution - 0222, Montreal, Quebec

Local Institution - 0037, Trois-Rivieres, Quebec

Local Institution - 0053, Santiago, Metropolitana

Local Institution - 0214, Santiago, Metropolitana

Local Institution - 0207, Hefei, Anhui

Local Institution - 0197, Hefei, Anhui

Local Institution - 0182, Beijing, Beijing

Local Institution - 0179, Beijing, Beijing

Local Institution - 0216, Beijing, Beijing

Local Institution - 0217, Fuzhou, Fujian

Local Institution - 0219, Fuzhou, Fujian

Local Institution - 0199, Shantou, Guangdong

Local Institution - 0185, Harbin, Heilongjiang

Local Institution - 0193, Zhengzhou, Henan

Local Institution - 0195, Zhengzhou, Henan

Local Institution - 0194, Zhengzhou, Henan

Local Institution - 0249, Changsha, Hunan

Local Institution - 0212, Changsha, Hunan

Local Institution - 0201, Nanjing, Jiangsu

Local Institution - 0180, Changchun, Jilin

Local Institution - 0183, Xi'an, Shan3xi

Local Institution - 0215, Shanghai, Shanghai

Local Institution - 0200, Shanghai, Shanghai

Local Institution - 0184, Hangzhou, Zhejiang

Local Institution - 0247, Linhai, Zhejiang

Local Institution - 0220, Shenyang, Not set

Local Institution - 0248, Xi'An, Not set

Local Institution - 0059, Bogota, Not set

Local Institution - 0058, Medellin, Not set

Local Institution - 0224, Monteria, Not set

Local Institution - 0094, Pereira, Not set

Local Institution - 0083, Brno, Not set

Local Institution - 0008, Brno, Not set

Local Institution - 0006, Novy Jicin, Not set

Local Institution - 0099, Odense, Not set

Local Institution - 0116, Lille, Nord

Local Institution - 0114, Caen, Not set

Local Institution - 0112, Montpellier, Not set

Local Institution - 0113, Rennes Cedex, Not set

Local Institution - 0242, Toulouse, Not set

Local Institution - 0115, Villejuif, Not set

Local Institution - 0035, Hong Kong, Not set

Local Institution - 0070, Kowloon, Not set

Local Institution - 0085, Bergamo, Not set

Local Institution - 0039, Milano, Not set

Local Institution - 0084, Padova, Not set

Local Institution - 0240, Pisa, Not set

Local Institution - 0152, Akita-shi, Akita

Local Institution - 0104, Hirosaki-shi, Aomori

Local Institution - 0173, Kashiwa-shi, Chiba

Local Institution - 0169, Matsuyama-shi, Ehime

Local Institution - 0119, Matsuyama-shi, Ehime

Local Institution - 0174, Fukuoka-shi, Fukuoka

Local Institution - 0142, Fukuoka-shi, Fukuoka

Local Institution - 0103, Fukushima-shi, Fukushima

Local Institution - 0154, Gifu City, Gifu

Local Institution - 0176, Ota, Gunma

Local Institution - 0100, Hiroshima-Shi, Hiroshima

Local Institution - 0111, Sapporo-shi, Hokkaido

Local Institution - 0170, Akashi-shi, Hyogo

Local Institution - 0118, Kobe-shi, Hyogo

Local Institution - 0172, Kobe, Hyogo

Local Institution - 0171, Kanazawa, Ishikawa

Local Institution - 0229, Kagoshima-shi, Kagoshima

Local Institution - 0127, Isehara, Kanagawa

Local Institution - 0109, Kawasaki-shi, Kanagawa

Local Institution - 0105, Sagamihara-shi, Kanagawa

Local Institution - 0147, Yokohama-shi, Kanagawa

Local Institution - 0117, Yokohama-shi, Kanagawa

Local Institution - 0141, Kumamoto-shi, Kumamoto

Local Institution - 0120, Kamigyo-ku, Kyoto

Local Institution - 0144, Sendai, Miyagi

Local Institution - 0146, Niigata-shi, Niigata

Local Institution - 0135, Kurashiki-shi, Okayama

Local Institution - 0137, Okayama-shi, Okayama

Local Institution - 0221, Hirakata, Osaka

Local Institution - 0138, Osaka-shi, Osaka

Local Institution - 0098, Osakasayama, Osaka

Local Institution - 0107, Suita, Osaka

Local Institution - 0139, Takatsuki City, Osaka

Local Institution - 0230, Hidaka-shi, Saitama

Local Institution - 0175, Kitaadachi-gun, Saitama

Local Institution - 0143, Sunto-gun, Shizuoka

Local Institution - 0148, Shimotsuga-gun, Tochigi

Local Institution - 0106, Bunkyo-ku, Tokyo

Local Institution - 0110, Bunkyo-ku, Tokyo

Local Institution - 0136, Chuo-ku, Tokyo

Local Institution - 0128, Chuo-ku, Tokyo

Local Institution - 0126, Koto-ku, Tokyo

Local Institution - 0156, Minato-ku, Tokyo

Local Institution - 0245, Ota-ku, Tokyo

Local Institution - 0140, Shinagawa-ku, Tokyo

Local Institution - 0196, Shinjuku-Ku, Tokyo

Local Institution - 0155, Shinjuku-ku, Tokyo

Local Institution - 0231, Toyama-shi, Toyama

Local Institution - 0178, Wakayama-shi, Wakayama

Local Institution - 0238, Ube-shi, Yamaguchi

Local Institution - 0101, Chiba, Not set

Local Institution - 0153, Chiba, Not set

Local Institution - 0145, Kyoto, Not set

Local Institution - 0108, Shizuoka, Not set

Local Institution - 0129, Seongnam-si, Kyǒnggi-do

Local Institution - 0165, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0166, Busan, Not set

Local Institution - 0150, Daegu, Not set

Local Institution - 0149, Daejeon, Not set

Local Institution - 0236, Jeonju-si, Not set

Local Institution - 0235, Seoul, Not set

Local Institution - 0130, Seoul, Not set

Local Institution - 0177, Seoul, Not set

Local Institution - 0168, Seoul, Not set

Local Institution - 0151, Seoul, Not set

Local Institution - 0131, Seoul, Not set

Local Institution - 0123, Seoul, Not set

Local Institution - 0157, Ulsan, Not set

Local Institution - 0090, Tuxtla Gutierrez, Chiapas

Local Institution - 0102, Mexico, Distrito Federal

Local Institution - 0071, Merida, Yucatan

Local Institution - 0234, San Luis Potosi, Not set

Local Institution - 0092, Callao, Not set

Local Institution - 0060, Lima, Not set

Local Institution - 0093, Lima, Not set

Local Institution - 0024, Lublin, Not set

Local Institution - 0022, Warszawa, Not set

Local Institution - 0243, Porto, Not set

Local Institution - 0081, Bucuresti, Not set

Local Institution - 0079, Cluj-Napoca, Not set

Local Institution - 0076, Craiova, Not set

Local Institution - 0080, Suceava, Not set

Local Institution - 0089, Moscow, Not set

Local Institution - 0088, St Petersburg, Not set

Local Institution - 0033, Singapore, Central Singapore

Local Institution - 0034, Singapore, Not set

Local Institution - 0063, Barcelona, Not set

Local Institution - 0062, Madrid, Not set

Local Institution - 0158, Changhua County, Changhua

Local Institution - 0161, Tainan, TNN

Local Institution - 0163, Kaohsiung County, Not set

Local Institution - 0167, Kaohsiung, Not set

Local Institution - 0133, Kaohsiung, Not set

Local Institution - 0164, Keelung, Not set

Local Institution - 0132, Taichung, Not set

Local Institution - 0160, Tainan, Not set

Local Institution - 0124, Taipei, Not set

Local Institution - 0162, Taipei, Not set

Local Institution - 0134, Taipei, Not set

Local Institution - 0159, Taoyuan, Not set

Local Institution - 0096, Ankara, Not set

Local Institution - 0125, Diyarbakır, Not set

Local Institution - 0122, Edrine, Not set

Local Institution - 0069, London, Greater London

Local Institution - 0066, London, Greater London

Local Institution - 0031, Manchester, Greater Manchester

Local Institution - 0237, London, Not set

Local Institution - 0029, Surrey, Not set

Conditions: Various Advanced Cancer

Learn More ›

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

NCT04265872

Recruiting

The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas

Conditions: Breast Cancer

Learn More ›

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

NCT04158141

Terminated

This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or pencil beam scanning uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

01/29/2025

Locations: UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida +26 locations

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

Moffitt Cancer Center-International Plaza, Tampa, Florida

Moffitt Cancer Center - McKinley Campus, Tampa, Florida

Moffitt Cancer Center, Tampa, Florida

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Brigham and Women's Hospital, Boston, Massachusetts

Mayo Clinic in Rochester, Rochester, Minnesota

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

Memorial Sloan Kettering Monmouth, Middletown, New Jersey

Memorial Sloan Kettering Bergen, Montvale, New Jersey

Memorial Sloan Kettering Commack, Commack, New York

Memorial Sloan Kettering Westchester, Harrison, New York

Mount Sinai Hospital, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Memorial Sloan Kettering Nassau, Uniondale, New York

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

MD Anderson in The Woodlands, Conroe, Texas

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

M D Anderson Cancer Center, Houston, Texas

MD Anderson West Houston, Houston, Texas

MD Anderson League City, League City, Texas

MD Anderson in Sugar Land, Sugar Land, Texas

Swedish Medical Center-First Hill, Seattle, Washington

The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec

Conditions: Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8

Learn More ›

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

NCT03092518

Completed

Background: - Gastric cancer is a common and serious cancer. Standard treatment is chemotherapy drugs. Researchers want to see if a new treatment helps. It is surgical removal of the cancer and heated chemotherapy delivered to the abdominal cavity called Hyperthermic intraperitoneal chemotherapy (HIPEC). Objective: - To test if surgical removal of tumors plus heated intraperitoneal chemotherapy can improve survival in people with gastric cancers. Eligibility: - People ages 18 and older with... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/28/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Gastric Adenocarcinoma, Esophagogastric Junction, Gastric Cancer

Learn More ›

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772

Active Not Recruiting

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

01/28/2025

Locations: Research Site, Duarte, California +46 locations

Research Site, Duarte, California

Research Site, Los Angeles, California

Research Site, Sacramento, California

Research Site, Santa Monica, California

Research Site, New Haven, Connecticut

Research Site, Chicago, Illinois

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Grand Rapids, Michigan

Research Site, New York, New York

Research Site, Portland, Oregon

Research Site, Pittsburgh, Pennsylvania

Research Site, Houston, Texas

Research Site, Seattle, Washington

Research Site, Odense C, Not set

Research Site, Catania, Not set

Research Site, Napoli, Not set

Research Site, Orbassano, Not set

Research Site, Padova, Not set

Research Site, Varese, Not set

Research Site, Chuo-ku, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Koto-ku, Not set

Research Site, Nagoya-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Wakayama-shi, Not set

Research Site, Seongnam-si, Not set

Research Site, Seoul, Not set

Research Site, Amsterdam, Not set

Research Site, Maastricht, Not set

Research Site, Nijmegen, Not set

Research Site, Rotterdam, Not set

Research Site, Drammen, Not set

Research Site, Oslo, Not set

Research Site, Trondheim, Not set

Research Site, A Coruña, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Sevilla, Not set

Research Site, Stockholm, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

NCT03323463

Active Not Recruiting

The purpose of this study is to demonstrate that participants with HPV positive and hypoxia negative T1-2, N1-2c (AJCC, 7th ed.) oropharyngeal squamous cell carcinoma receiving a major de-escalated radiation therapy with 2 cycles of standard chemotherapy is not inferior to comparable subjects treated with the current standard chemoradiation. Accrual for Cohort A has been completed. Cohort B is active and continues to enroll participants where surgery is optional and proton is allowed.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/27/2025

Locations: Hartford Healthcare (Data Collection), Hartford, Connecticut +9 locations

Conditions: HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck

Learn More ›

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

NCT06477692

Recruiting

To determine the risk of solitary elective volume recurrence following involved nodal radiotherapy (INRT) versus elective nodal irradiation (ENI)

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

01/24/2025

Locations: UT Southwestern Medical Center, Dallas, Texas

Conditions: Head and Neck Cancer

Learn More ›

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

NCT03777657

Completed

This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/24/2025

Locations: University of California Davis Health System, Sacramento, California +148 locations

University of California Davis Health System, Sacramento, California

Southeastern Regional Medical Center, Newnan, Georgia

Ohio State University Hospital, Columbus, Ohio

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Reading Hospital, West Reading, Pennsylvania

Tennessee Oncology, Pllc Nashville, Nashville, Tennessee

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui

Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui

The Second Hospital of Anhui Medical University, Hefei, Anhui

Peking University Third Hospital, Beijing, Beijing

Beijing Chao Yang Hospital, Beijing, Beijing

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing

Beijing Cancer Hospital, Beijing, Beijing

Peking Union Medical College Hospital, Beijing, Beijing

Chinese Pla General Hospital, Beijing, Beijing

Beijing Luhe Hospital, Capital Medical University, Beijing, Beijing

Daping Hospital, Third Military Medical University, Chongqing, Chongqing

The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian

Fujian Cancer Hospital, Fuzhou, Fujian

The First Hospital of Lanzhou University, Lanzhou, Gansu

Foshan First Peoples Hospital, Foshan, Guangdong

Sun Yat Sen University Cancer Center, Guangzhou, Guangdong

Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong

Shenzhen Peoples Hospital, Shenzhen, Guangdong

Affiliated Hospital of Guilin Medical University, Guilin, Guangxi

Hainan General Hospital, Haikou, Hainan

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Henan Cancer Hospital, Zhengzhou, Henan

Henan Provincial Peoples Hospital, Zhengzhou, Henan

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Hubei Cancer Hospital, Wuhan, Hubei

Xiangya Hospital of Central South University, Changsha, Hunan

Hunan Cancer Hospital, Changsha, Hunan

Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu

Nantong Tumor Hospital Branch South, Nantong, Jiangsu

The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

The First Hospital of Jilin University, Changchun, Jilin

The First Hospital of China Medical University, Shenyang, Liaoning

The General Hospital of Shenyang Military, Shenyang, Liaoning

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Shandong Cancer Hospital, Jinan, Shandong

Linyi Cancer Hospital, Linyi, Shandong

The Affiliated Hospital of Qingdao University Branch South, Qingdao, Shandong

Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai

Affiliated Zhongshan Hospital of Fudan University, Shanghai, Shanghai

Shanghai General Hospital, Shanghai, Shanghai

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai

Tianjin Medical University General Hospital, Tianjin, Tianjin

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin

Yunnan Cancer Hospital, Kunming, Yunnan

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

Centre Georges Francois Leclerc, Dijon, Not set

Chu Besancon Hopital Jean Minjoz, Doubs, Not set

Hopital de La Timone, Marseille, Not set

Icl Alexis Vautrin, Meurthe Et Moselle, Not set

Hopital Nord Franche Comte Site Du Mittan, Montbeliard, Not set

Centre Antoine Lacassagne, Nice, Not set

Chu Bordeaux Hopital Haut Leveque, Pessac, Not set

Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi, Bologna, Not set

Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Not set

Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Not set

Iov Istituto Oncologico Veneto Irccs, Padova, Not set

Ao Ospedali Riuniti Marche Nord, Pesaro, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Not set

Irccs Ospedale Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Not set

Aou Senese Policlinico Santa Maria Alle Scotte, Siena, Not set

Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino, Torino, Not set

Azienda Ospedaliera Universitaria Delle Marche, Torrette, Not set

Chiba Cancer Center, Chibashi, Chiba

Tesshokai Kameda General Hospital, Kamogawashi, Chiba

Nho Shikoku Cancer Center, Matsuyamashi, Ehime

Nho Kyushu Cancer Center, Fukuokashi, Fukuoka

Gunma Prefectural Cancer Center, Otashi, Gunma

Hokkaido University Hospital, Sapporoshi, Hokkaido

Johas Kansai Rosai Hospital, Amagasakishi, Hyogo

Ishikawa Prefectural Central Hospital, Kanazawashi, Ishikawa

Kagawa University Hospital, Kitagun, Kagawa

Kanagawa Cancer Center, Yokohamashi, Kanagawa

Oita University Hospital, Yufushi, Oita

Kurashiki Central Hospital, Kurashikishi, Okayama

Okayama University Hospital, Okayamashi, Okayama

Izumi City General Hospital, Izumishi, Osaka

Nho Osaka National Hospital, Osakashi, Osaka

Osaka University Hospital, Suitashi, Osaka

Saitama Medical University International Medical Center, Hidakashi, Saitama

Saitama Cancer Center, Kitaadachigun, Saitama

Hamamatsu University School of Medicine, University Hospital, Hamamatsushi, Shizuoka

National Cancer Center Hospital, Chuoku, Tokyo

Tokyo Metropolitan Tama Medical Center, Fuchushi, Tokyo

Cancer Institute Hospital of Jfcr, Kotoku, Tokyo

Center Hospital of the National Center For Global Health and Medicine, Shinjukuku, Tokyo

National Cancer Center, Goyangsi, Gyeonggi-do

Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do

The Catholic University of Korea, St Vincents Hospital, Suwonsi, Gyeonggi-do

Ajou University Hospital, Suwonsi, Gyeonggi-do

Kyungpook National University Chilgok Hospital, Daegu, Gyeongsangbukdo

Chonnam National University Hwasun Hospital, HwasunGun, Jeollanam-do

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi

Asan Medical Center, Seoul, Seoul Teugbyeolsi

Chung Ang University Hospital, Seoul, Seoul Teugbyeolsi

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Centrum Terapii Wspolczesnej Jm Jasnorzewska Sp Komandytowo Akcyjna, Lodz, Not set

Przychodnia Med Polonia Sp Z Oo, Poznan, Not set

Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy, Warszawa, Not set

Pan American Oncology Trials, Llc, Rio Piedras, Not set

Arkhangelsk Regional Clinical Oncological Dispensary, Arkhangelsk, Arkhangel'skaya Oblast'

Rbih Ivanovo Regional Oncological Dispensary, Ivanovo, Ivanovskaya Oblast'

Vitamed Llc, Moscow, Moskva

Sbhi of Novosibirsk Region Novosibirsk Regional Oncological Dispensary, Novosibirsk, Novosibirskaya Oblast'

Bih of Omsk Region Clinical Oncology Dispensary, Omsk, Omskaya Oblast'

Private Educational Institution of Higher Education Medical University Reaviz, Samara, Samaraskaya Oblast'

Pavlov First Saint Petersburg State Medical University, SaintPetersburg, Sankt-Peterburg

Fsbi Clinical Research and Practical Center For Specialized Medical Care (Oncology), SanktPetersburg, Sankt-Peterburg

State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary, Volgograd, Volgogradskaya Oblast'

Sbih of Yaroslavl Region Regional Clinical Oncological Hospital, Yaroslavl, Yaroslavskaya Oblast'

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital de Basurto, Bilbao, Not set

Hospital General Universitario de Elche, Elche, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Hm Madrid Sanchinarro, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Not set

Hospital Regional Universitario de Malaga, Malaga, Not set

Complejo Hospitalario de Navarra, Pamplona, Not set

Hospital Universitario Virgen Del Rocio, Sevilla, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Initia Oncologia, Slp, Valencia, Not set

Hospital Universitario Miguel Servet, Zaragoza, Not set

Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Not set

National Cheng Kung University Hospital, Tainan, Not set

Taipei Veterans General Hospital, Taipei, Not set

Acibadem Adana Hospital, Adana, Not set

Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital, Ankara, Not set

Nonu Universitesi Tip Fakultesi, Battalgazi, Not set

Dicle University Medical Faculty, Diyarbakir, Not set

Akdeniz University Hospital, Konyaalt, Not set

Iu C, Clinical Research Excellence Application and Research Center, Stanbul, Not set

Namik Kemal University, Tekirdag, Not set

Karadeniz Tecnical Uni Med Fac, Trabzon, Not set

Velindre Cancer Centre, Cardiff, Not set

Sarah Cannon Research Institute Uk, London, Not set

Conditions: Gastric, or Gastroesophageal Junction Adenocarcinoma

Learn More ›

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

NCT02908477

Completed

This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy. This study investigates a less intense radiation treatment following surgery that uses half the dose of radiation given over two weeks rather than six weeks. Patients will be randomly assigned to receive the less intense treatment versus the traditional treatment by coin flip. Patients are... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations

Conditions: Oropharynx Cancer

Learn More ›

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257

Active Not Recruiting

This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: OPN-Glendale, Arcadia, California +128 locations

OPN-Glendale, Arcadia, California

OPN-Los Alamitos, Los Alamitos, California

Southern California Permanente Group, Los Angeles, California

Emad Ibrahim, MD, Inc, Redlands, California

Providence Medical Foundation, Santa Rosa, California

Lutheran Medical Center - Cancer Centers of Colorado, Golden, Colorado

Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut

Cancer Specialists of North Florida, Jacksonville, Florida

Mid Florida Hematology and Oncology Center, Orange City, Florida

Advent Health Orlando, Orlando, Florida

Napa Research, Pompano Beach, Florida

Kansas University Mediacal Center, Fairway, Kansas

Pontchartrain Cancer Center, Covington, Louisiana

Tulane University, New Orleans, Louisiana

Health Partners, Bloomington, Minnesota

Renown Health, Reno, Nevada

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Montefiore Medical Center, Bronx, New York

New York City Health+HospitalsCorporation Elmhurst Hospital Center, Elmhurst, New York

Northwell Health, Queens, New York

Cleveland Clinic Mercy Hospital, Canton, Ohio

Gabrail Cancer Center, Canton, Ohio

Tricounty Hematology and Oncology Associates, Massillon, Ohio

Kaiser Permanente Northwest, Portland, Oregon

The Center for Cancer and Blood Disorders, Fort Worth, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Millennium Research & Clinical Development, Houston, Texas

Pro Research Tools, INC DBA Lumi Research, Kingwood, Texas

The University of Texas - Hope Cancer Center, Tyler, Texas

Innova Schar Cancer Insitute, Fairfax, Virginia

Northwest Medical Specialties, Tacoma, Washington

Klinikum Klagenfurt am Worthersee, Klagenfurt am Worthersee, Not set

Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Not set

Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie, c/o Klinik Floridsdorf Abteilung für Innere Medizin und Pneumologie, Wien, Not set

Karl Landsteiner Institute for Lung Research and Pneumological Oncology, c/o Klinik Floridsdorf Department for Inner Medicine und Pneumology, Wien, Not set

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui

Anhui Chest Hospital, Hefei, Anhui

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing

Beijing Cancer Hospital, Beijing, Beijing

The First Affiliated Hospital of Chongqing Medical, Chongqing, Chongqing

Chongqing University Cancer Hospital, Chongqing, Chongqing

Fujian Cancer Hospital, Fuzhou, Fujian

The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong

Peking University Shenzhen Hospital, Shenzhen, Guangdong

The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi

Guangxi Medical University Cancer Hospital, Nanning, Guangxi

Gungzhouyikedaxuefushuzhongliuyiyuan, Guangzhou, Guangzhou

Affiliated Hospital of Hebei University, Baoding, Hebei

Cangzhou People's Hospital, Cangzhou, Hebei

Tangshan People's Hospital, Tangshan, Hebei

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Jiamusi Cancer Hospital, Jiamusi, Heilongjiang

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan

Henan Cancer Hospital, Zhengzhou, Henan

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Hong Kong United Oncology Centre, Hong kong, Hong Kong

Queen Elizabeth Hospital, Hong Kong, Hong Kong

Queen Mary Hospital, Hong Kong, Hong Kong

TaiHe Hospital Affiliated Hospital of Hubei University of Medicine, Shiyan, Hubei

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei

Zhongnan hospital of wuhan university, Wuhan, Hubei

Hubei Cancer Hospital, Wuhan, Hubei

The First People's Hospital Of Changde City, Changde, Hunan

The Second Xiangya Hospita, Changsha, Hunan

Hunan Cancer Hospital, Changsha, Hunan

Xiangya Hospital Central South University, Changsha, Hunan

Xuzhou Central Hospital, Xuzhou, Jiangsu

Northern Jiangsu people's Hospital, Yangzhou, Jiangsu

First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi

Ganzhou Cancer Hospital, Ganzhou, Jiangxi

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

Jilin Cancer Hospital, Changchun, Jilin

Liaoning Cancer Hospital & Institute, Shenyang, Liao Ning

Shenyang The Tenth People's Hospital, Shenyang, Liao Ning

Qilu Hospital of Shandong University, Jinan, Shandong

Shandong Cancer Hospital, Jinan, Shandong

Linyi Tumor Hospital, Linyi, Shandong

Affiliated Hospital of Qingdao University, Qingdao, Shandong

Shanghai Chest Hospital, Shanghai, Shanghai

Fudan University Shanghai Cancer Center, Shanghai, Shanghai

Zhongshan Hospital of Fudan University, Shanghai, Shanghai

Wenzhou University Hospital, Wenzhou, Shanghai

Baoji Central Hospital, Baoji, Shanxi

Shanxi Provincial Cancer Hospital, TaiYuan, Shanxi

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi

West China Hospital of Sichuan University, Chengdu, Sichuan

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin

Tianjin Medical University General Hospital, Tianjin, Tianjin

The Second People's Hospital Of Yibin, Sichuan, Yibin

Yunnan Cancer Hospital, Kunming, Yunnan

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang

Yuhang Branch of the First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang

Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang

The 1st Affiliated Hospital of WMU, Wenzhou, Zhejiang

University Hospital Brno (Clinic For Lung Diseases and Tuberculosis), Brno, Not set

University Hospital Brno, Brno, Not set

University Hospital Olomouc (Oncology Clinic), Olomouc, Not set

University Hospital Ostrava (oncology department), Ostrava-Poruba, Not set

University Hospital Ostrava, Ostrava-Poruba, Not set

Nemocnice AGEL Ostrava-Vítkovice, Ostrava-Vitkovice, Not set

Nemocnice AGEL Ostrava-Vítkovice, Ostrava-Vítkovice, Not set

University Hospital Motol, Prague, Not set

University Hospital Motol (Pneumology Clinic 2.LF UK and FN Motol), Prague, Not set

General University hospital in Prague (Oncology department), Praha 2, Not set

Kliniken der Stadt Cologne GmbH, Cologne, Not set

University hospital Schleswig-Holstein, Lübeck-Travemünde, Not set

"Sotiria" Thoracic Diseases General Hospital of Athens, Athens, Not set

General Hospital of Athens "Alexandra", Athens, Not set

Fejer County Szent Gyorgy University Teaching Hospital, Szekesfehervar, Not set

Pulmonary Institute of Torokbalint, Torokbalint, Not set

Riga East University Hospital, Latvian Oncology Center, Riga, Not set

Clinic of Oncology, Pauls Stradins Clinical university hospital, Riga, Not set

Hospital St. Jansdal, Harderwijk, Not set

Isala Hospital, Zwolle, Not set

MedPoloniaSp. z o.o., Poznan, Not set

Lung and Chest Cancer Clinic, National Institute of Oncology, Warszawa, Not set

Hospital Universitario de Badajoz, Badajoz, Not set

Hospital German Trias i Pujol/ ICO Badalona, Badalona, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Universitario Reina Sofía, Cordoba, Not set

Hospital Gregorio Marañon, Madrid, Not set

Hospital Universitario Puerta de Hierro, Madrid, Not set

Hospital Quironsalud Sagrado Corazón, Sevilla, Not set

Hospital Marques de Valdecilla, Valdecilla, Not set

University Hospital La Fe, Valencia, Not set

Conditions: Limited-Stage Small Cell Lung Cancer

Learn More ›

Browse by State

Cisplatin treatment options in Alabama

Cisplatin treatment options in Alaska

Cisplatin treatment options in Arizona

Cisplatin treatment options in Arkansas

Cisplatin treatment options in California

Cisplatin treatment options in Colorado

Cisplatin treatment options in Connecticut

Cisplatin treatment options in Delaware

Cisplatin treatment options in District of Columbia

Cisplatin treatment options in Florida

Cisplatin treatment options in Georgia

Cisplatin treatment options in Hawaii

Cisplatin treatment options in Idaho

Cisplatin treatment options in Illinois

Cisplatin treatment options in Indiana

Cisplatin treatment options in Iowa

Cisplatin treatment options in Kansas

Cisplatin treatment options in Kentucky

Cisplatin treatment options in Louisiana

Cisplatin treatment options in Maine

Cisplatin treatment options in Montana

Cisplatin treatment options in Nebraska

Cisplatin treatment options in Nevada

Cisplatin treatment options in New Hampshire

Cisplatin treatment options in New Jersey

Cisplatin treatment options in New Mexico

Cisplatin treatment options in New York

Cisplatin treatment options in North Carolina

Cisplatin treatment options in North Dakota

Cisplatin treatment options in Ohio

Cisplatin treatment options in Oklahoma

Cisplatin treatment options in Oregon

Cisplatin treatment options in Maryland

Cisplatin treatment options in Massachusetts

Cisplatin treatment options in Michigan

Cisplatin treatment options in Minnesota

Cisplatin treatment options in Mississippi

Cisplatin treatment options in Missouri

Cisplatin treatment options in Pennsylvania

Cisplatin treatment options in Rhode Island

Cisplatin treatment options in South Carolina

Cisplatin treatment options in South Dakota

Cisplatin treatment options in Tennessee

Cisplatin treatment options in Texas

Cisplatin treatment options in Utah

Cisplatin treatment options in Vermont

Cisplatin treatment options in Virginia

Cisplatin treatment options in Washington

Cisplatin treatment options in West Virginia

Cisplatin treatment options in Wisconsin

Cisplatin treatment options in Wyoming